PNC Financial Services Group
AVBP icon

PNC Financial Services Group’s ArriVent BioPharma AVBP Stock Holding History

PNC Financial Services Group’s Portfolio AVBP Stock Details AVBP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$7.52K Buy
326
+189
+138% +$4.27K ﹤0.01% 4076
2025
Q4 		$2.76K Buy
137
+129
+1,613% +$2.69K ﹤0.01% 4446
2025
Q3 		$148 Buy
+8
New +$157 ﹤0.01% 4965

Other funds holding AVBP

SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
IAM
Infinitum Asset Management Fort Lauderdale, Florida $801M AUM 8.83% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
SI
Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

PNC Financial Services Group's AVBP Position: Q1 2026 in Review

PNC Financial Services Group increased its ArriVent BioPharma (AVBP) stake by 138% in Q1 2026, buying an estimated $4.27K and bringing the position to 326 shares worth $7.52K. The position accounts for ﹤0.01% of the portfolio, ranked #4076.

PNC Financial Services Group first reported a position in AVBP in Q3 2025 and has held it in 3 quarters since. 139 funds tracked by Wall St. Rank hold AVBP as of Q1 2026.

  • PNC Financial Services Group held 326 shares of ArriVent BioPharma worth $7.52K as of Q1 2026.
  • PNC Financial Services Group bought 189 ArriVent BioPharma shares in Q1 2026, an estimated $4.27K.
  • ArriVent BioPharma made up ﹤0.01% of PNC Financial Services Group's portfolio in Q1 2026, its #4076 holding.
  • PNC Financial Services Group first reported a position in ArriVent BioPharma in Q3 2025 and has held it in 3 quarters since.
  • 139 funds tracked by Wall St. Rank held ArriVent BioPharma as of Q1 2026.

Based on PNC Financial Services Group's 13F filing for Q1 2026, filed 8 May 2026.